Literature DB >> 32961253

Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening.

Gabriele Pagani1, Federico Conti2, Andrea Giacomelli2, Dario Bernacchia2, Rossana Rondanin3, Andrea Prina3, Vittore Scolari4, Cecilia Eugenia Gandolfi5, Silvana Castaldi6, Giuseppe Marano5, Cosimo Ottomano7, Patrizia Boracchi5, Elia Biganzoli5, Massimo Galli2.   

Abstract

Entities:  

Keywords:  COVID-19; Italy; Mass screening; SARS-CoV-2; Seroprevalence

Mesh:

Substances:

Year:  2020        PMID: 32961253      PMCID: PMC7836634          DOI: 10.1016/j.jinf.2020.09.021

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, We read with interest the article by C. Dimeglio and colleagues, in which the authors apply a mathematical model to conclude that a SARS-CoV-2 (Severe Acute Respiratory Sindrome Coronavirus 2) seroprevalence of at least 50% is required to avoid an infection rebound after removal of containment measures. In our study we found that SARS-CoV-2 seroprevalence was dramatically lower than this threshold, even in an area of initially unrestricted viral circulation. Italy was the first European country that suffered a wide spread of Coronavirus Disease 2019 (COVID-19), caused by a novel betacoronavirus which was first identified in China and denominated SARS-CoV-2 (Severe Acute Respiratory Sindrome Coronavirus 2), which caused hundreds of thousands of cases. During the epidemic, testing was restricted to severely symptomatic cases. Consequently, the true extent of the SARS-CoV-2 infection remains unknown. We estimated SARS-CoV-2 seroprevalence in the municipality of Castiglione d'Adda, a rural town of about 4550 inhabitants located South-East of Milan, which has been heavily affected by SARS-CoV-2 infection since the earliest stages of the epidemic. As of June 21, 2020, 184 confirmed cases of COVID-19 were reported, the large majority of which requiring hospitalization, accounting for about 4% of the total population. At the same time, 47 deaths were officially attributed to COVID-19. In this study, the entire population of Castiglione D'Adda was invited to perform a lateral-flow immunocromatographic tests on capillary blood (Prima Lab, Switzerland) from the 18th of May to the 7th of June. News about the mass screening was disseminated by the town municipality. A random sample of 562 subjects (stratified per sex and age) was invited to undergo confirmatory tests by chemiluminescent method on venipuncture drawn blood (CLIA, IgG anti-SARS-CoV-2, Abbott, USA) and SARS-CoV-2 PCR on NPS, regardless of RICT results. More detailed information about the randomization procedure and the study design are available on the complete protocol, published on medrXiv pre-print server. The analysis of IgG prevalence in the different age groups was performed by logistic regression models with response variable equal to 1 for positive IgG results, and 0 for negative IgG results. Age and gender were included as independent variables. Results were reported in terms of estimated probabilities of being positive to IgG test as a function of age, with respective 95% confidence intervals. Results presented in this paper are based on 509 people selected in the random sample who agreed to undergo venipuncture to perform CLIA serologies. Characteristics of the selected population are reported in Table 1 .
Table 1

Characteristics of 509 subjects in the random sample.

IgG negative (n = 394)IgG positive (n = 115)
Gender (Female)200 (50•8%)49 (42•6%)
Age (years; median, SD)46•0, 20•655•4, 19•5
Age groups:
 0–1956 (91•8%)5 (8•2%)
 20–3992 (82•9%)19 (17•1%)
 40–59142 (78•0%)40 (22•0%)
 ≥ 60104 (67•1%)51 (32•9%)
Contact with verified case93 (23•6%)61 (53•0%)
Smoker92 (23•4%)10 (8•7%)
Cardiovascular diseases
 CAD/MI10 (2•5%)3 (4•3%)
 Arrhythmias14 (3•6%)5 (4•3%)
 Hypertension68 (17•3%)32 (27•8%)
 Other14 (3•6%)14 (12•2%)
At least one of the above:84 (21•3%)47 (40•9%)
Rheumatic diseases19 (4•8%)11 (9•6%)
Diabetes mellitus12 (3•0%)6 (6•2%)
Chronic Lung diseases
 Asthma20 (5•1%)2 (1•7%)
 COPD1 (0•3%)1 (0•9%)
 Other9 (2•3%)4 (3•5%)
At least one of the above:29 (7•4%)7 (6•1%)
Oncological pathologies
Solid Tumors20 (5•1%)6 (5•2%)
Oncochematological2 (0•5%)2 (1•7%)
At least one of the above:22 (5•6%)8 (7•0%)
Symptomatic
 Fever65 (16•5%)66 (57•4%)
 Cough57 (14•5%)31 (27•0%)
 Anosmia23 (5•8%)37 (32•2%)
 Dysgeusia27 (6•9%)46 (40•0%)
 Dispnea23 (5•8%)13 (11•3%)
 Rush:11 (2•8%)4 (3•5%)
 Arthromyalgia34 (8•6%)36 (31•3%)
At least one of the above:124 (31•5%)89 (77•4%)
Other symptoms54 (13•7%)23 (20•0%)

Numerical variables are presented as means.

CAD: Coronary Artery Disease; MI: Miocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease.

Characteristics of 509 subjects in the random sample. Numerical variables are presented as means. CAD: Coronary Artery Disease; MI: Miocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease. The overall seroprevalence found in the tested sample was 22.6% (95% confidence interval 17.2%- 29.1%). Interestingly, seroprevalence increases with increasing age (as shown in Table 1). In multivariate analyses, a significant effect of age was found (p<0.0001) while no significant association between IgG positivity and gender emerged (p = 0.2560). The possible existence of a non-linear effect of age was tested by including spline polynomials, without significant results (p = 0.9078). Furthermore, an age/gender interaction effect did not result significant (p = 0.5199). Estimates of probabilities of being positive to IgG test, from a model including only age as independent variable, are reported in Fig. 1 .
Fig. 1

Estimated probability of IgG positivity as a function of age

Solid line: estimates, dashed lines: 95% confidence intervals.

Estimated probability of IgG positivity as a function of age Solid line: estimates, dashed lines: 95% confidence intervals. Since the early phases of the pandemic, advanced age was identified as an independent predictor for severe disease and worse outcomes. Beside this, it remains unclear if the limited number of cases reported in children is due to a milder course of disease, with a larger percentage of asymptomatic cases, or to a lower susceptibility to infection, as our results seem to suggest. Different ACE2 expression according to age have been postulated to explain clinical expression and susceptibility to the infection. In particular, a higher expression of ACE2 in lung tissues in advanced age groups had been speculated , . Moreover, a variable susceptibility to other coronavirus such as HCoV-NL63, which also use ACE2 as cell receptor in humans, in different age groups, has been also reported in different age groups. Another possible explanation may be that an asymptomatic/pauci-symptomatic infection, more common in younger subjects, could elicit a less marked, or transient, antibody response, as already found in the closely related Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A possible confounding factor in our findings could be related to social distancing measures: schools of any grade were among the first institutions to be closed in Italy, starting from the 5th of March. This could have led to a lower exposure to the infection in children in pre-scholar and scholar age groups. In conclusion, our findings suggest that SARS-CoV-2 IgG seroprevalence increases with increasing age and these data suggest a lower susceptibility to infection in the lower age groups. These findings have important implications in epidemiology and public health, particularly in designing future population screenings, and could be an important contribution in the re-opening process, especially considered that more than three-fourths of the population could be still susceptible to SARS-CoV-2 infection, even in an area of initially unrestricted viral circulation.

Declaration of Competing Interests

The authors declare no conflicts of interest. All authors have seen and approved the final manuscript.
  7 in total

1.  MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.

Authors:  Pyoeng Gyun Choe; R A P M Perera; Wan Beom Park; Kyoung-Ho Song; Ji Hwan Bang; Eu Suk Kim; Hong Bin Kim; Long Wei Ronald Ko; Sang Won Park; Nam-Joong Kim; Eric H Y Lau; Leo L M Poon; Malik Peiris; Myoung-Don Oh
Journal:  Emerg Infect Dis       Date:  2017-07-15       Impact factor: 6.883

2.  The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France.

Authors:  Chloé Dimeglio; Jean-Michel Loubes; Benjamin Deporte; Martine Dubois; Justine Latour; Jean-Michel Mansuy; Jacques Izopet
Journal:  J Infect       Date:  2020-04-29       Impact factor: 6.072

3.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

4.  Are children less susceptible to COVID-19?

Authors:  Ping-Ing Lee; Ya-Li Hu; Po-Yen Chen; Yhu-Chering Huang; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2020-02-25       Impact factor: 4.399

5.  Epidemiology of human coronavirus NL63 infection among hospitalized patients with pneumonia in Taiwan.

Authors:  Su-Hua Huang; Mei-Chi Su; Ni Tien; Chien-Jhen Huang; Yu-Ching Lan; Chen-Sheng Lin; Chao-Hsien Chen; Cheng-Wen Lin
Journal:  J Microbiol Immunol Infect       Date:  2015-11-19       Impact factor: 4.399

Review 6.  Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor.

Authors:  Yanwei Li; Wei Zhou; Li Yang; Ran You
Journal:  Pharmacol Res       Date:  2020-04-14       Impact factor: 7.658

Review 7.  Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).

Authors:  Arno R Bourgonje; Amaal E Abdulle; Wim Timens; Jan-Luuk Hillebrands; Gerjan J Navis; Sanne J Gordijn; Marieke C Bolling; Gerard Dijkstra; Adriaan A Voors; Albert Dme Osterhaus; Peter Hj van der Voort; Douwe J Mulder; Harry van Goor
Journal:  J Pathol       Date:  2020-06-10       Impact factor: 9.883

  7 in total
  26 in total

1.  Verifying the real estimates of COVID-19 deaths in Africa.

Authors:  Olayinka Stephen Ilesanmi; Aanuoluwapo Adeyimika Afolabi
Journal:  Germs       Date:  2020-12-28

2.  Seroprevalence of SARS-CoV-2 among high-risk healthcare workers in a MERS-CoV endemic area.

Authors:  Fayhan Alroqi; Emad Masuadi; Lulwah Alabdan; Maysa Nogoud; Modhi Aljedaie; Ahmad S Abu-Jaffal; Tlili Barhoumi; Abdulrahman Almasoud; Naif Khalaf Alharbi; Abdulrahman Alsaedi; Mohammad Khan; Yaseen M Arabi; Amre Nasr
Journal:  J Infect Public Health       Date:  2021-08-25       Impact factor: 7.537

3.  Seroprevalence of SARS-CoV-2 Assessed by Four Chemiluminescence Immunoassays and One Immunocromatography Test for SARS-Cov-2.

Authors:  Pellegrino Cerino; Alfonso Gallo; Biancamaria Pierri; Carlo Buonerba; Denise Di Concilio; Maria Concetta Cuomo; Lucia Vassallo; Gabriella Lo Conte; Annachiara Coppola; Antonio Pizzolante; Giovanni Boccia; Veronica Ferrucci; Luigi Atripaldi; Maria Triassi; Daniela Pacella; Michele Cennamo; Paolo Romano; Teresa Maria Sorbo; Alessandro Furno; Oriana Catapano; Aldo Contina; Giuseppe Perruolo; Maurizio D'Amora; Daniela Terracciano; Giuseppe Portella
Journal:  Front Public Health       Date:  2021-04-29

4.  Multiple relationships between aerosol and COVID-19: A framework for global studies.

Authors:  Yaxin Cao; Longyi Shao; Tim Jones; Marcos L S Oliveira; Shuoyi Ge; Xiaolei Feng; Luis F O Silva; Kelly BéruBé
Journal:  Gondwana Res       Date:  2021-02-09       Impact factor: 6.051

5.  Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.

Authors:  Andrew T Levin; William P Hanage; Nana Owusu-Boaitey; Kensington B Cochran; Seamus P Walsh; Gideon Meyerowitz-Katz
Journal:  Eur J Epidemiol       Date:  2020-12-08       Impact factor: 8.082

6.  Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.

Authors:  Laura Pezzati; Andrea Giacomelli; Davide Mileto; Federico Conti; Gloria Gagliardi; Alberto Rizzo; Laura Milazzo; Marco Schiuma; Alice Covizzi; Matteo Siano; Cinzia Bassoli; Matteo Passerini; Marco Piscaglia; Alessandro Torre; Letizia Oreni; Giuliano Rizzardini; Massimo Galli; Anna Lisa Ridolfo; Spinello Antinori
Journal:  J Infect       Date:  2021-05-29       Impact factor: 38.637

7.  Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.

Authors:  Anne Gégout Petit; Hélène Jeulin; Karine Legrand; Nicolas Jay; Agathe Bochnakian; Pierre Vallois; Evelyne Schvoerer; Francis Guillemin
Journal:  Viruses       Date:  2021-06-04       Impact factor: 5.048

8.  Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis.

Authors:  Omar Irfan; Jiang Li; Kun Tang; Zhicheng Wang; Zulfiqar A Bhutta
Journal:  J Glob Health       Date:  2021-07-17       Impact factor: 4.413

9.  Low impact of SARS-CoV-2 infection among paediatric acute respiratory disease hospitalizations.

Authors:  Maria Melé; Desiree Henares; Rosa Pino; Silvia Asenjo; Rocío Matamoros; Victoria Fumadó; Claudia Fortuny; Juan-José García-García; Iolanda Jordan; Pedro Brotons; Carmen Muñoz-Almagro; Mariona-Fernández de-Sevilla; Cristian Launes
Journal:  J Infect       Date:  2020-10-21       Impact factor: 6.072

10.  Seroprevalence of Anti-SARS-CoV-2 IgG and IgM among Adults over 65 Years Old in the South of Italy.

Authors:  Immacolata Polvere; Alfredina Parrella; Giovanna Casamassa; Silvia D'Andrea; Annamaria Tizzano; Gaetano Cardinale; Serena Voccola; Piercarmine Porcaro; Romania Stilo; Pasquale Vito; Tiziana Zotti
Journal:  Diagnostics (Basel)       Date:  2021-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.